Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 03 Oct 2024 New trial record